Combinations of phosphoinositide 3-kinase inhibitor compounds chemotherapeutic agents, and methods of use

US8604014B2 · kind B2 · utility

Assignees

• Genentech, Inc. · US
• F. Hoffmann-La Roche AG · CH

Inventors

• Marcia Belvin · South San Francisco, US
• Lori Friedman · Redwood City, US
• Klaus Hoeflich · San Mateo, US
• Deepak Sampath · South San Francisco, US
• Ulka Vijapurkar · Millbrae, US
• Jeffrey Wallin · South San Francisco, US
• Leisa Johnson · Lafayette, US
• Mallika Singh · San Francisco, US
• Sonal Patel · Abingdon, GB

Key dates

• Filing date: May 17, 2011
• Grant date: Dec 10, 2013
• Expiry date: May 17, 2031

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y10T436/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Combinations of PI3K inhibitor compounds having Formulas I and II and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hyperproliferative disorders such as cancer. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.